Overview

Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Changes in insulin resistance in healthy volunteers with normal body weight (BMI 18-25) after 14 days of STRIBILD®-, Truvada®/Kaletra® or Truvada®/Prezista®/Norvir® intake, measured by hyperinsulinemic euglycemic clamp.
Phase:
Phase 1
Details
Lead Sponsor:
Technische Universität München
Collaborators:
Gilead Sciences
MUC Research GmbH
Treatments:
Cobicistat
Darunavir
Elvitegravir
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Insulin
Lopinavir
Ritonavir
Tenofovir